A detailed history of Ally Bridge Group (Ny) LLC transactions in Context Therapeutics Inc. stock. As of the latest transaction made, Ally Bridge Group (Ny) LLC holds 1,757,524 shares of CNTX stock, worth $3.23 Million. This represents 2.45% of its overall portfolio holdings.

Number of Shares
1,757,524
Previous 1,886,232 6.82%
Holding current value
$3.23 Million
Previous $3.77 Million 8.7%
% of portfolio
2.45%
Previous 3.54%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.79 - $2.66 $230,387 - $342,363
-128,708 Reduced 6.82%
1,757,524 $3.44 Million
Q2 2024

Aug 14, 2024

BUY
$1.24 - $2.19 $1.44 Million - $2.54 Million
1,160,281 Added 159.83%
1,886,232 $3.77 Million
Q3 2023

Nov 14, 2023

BUY
$0.9 - $1.59 $65,299 - $115,362
72,555 Added 11.1%
725,951 $1.1 Million
Q2 2023

Aug 14, 2023

BUY
$0.48 - $1.6 $313,630 - $1.05 Million
653,396 New
653,396 $1.05 Million

Others Institutions Holding CNTX

About Context Therapeutics Inc.


  • Ticker CNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,966,100
  • Market Cap $29.4M
  • Description
  • Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therape...
More about CNTX
Track This Portfolio

Track Ally Bridge Group (Ny) LLC Portfolio

Follow Ally Bridge Group (Ny) LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ally Bridge Group (Ny) LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ally Bridge Group (Ny) LLC with notifications on news.